This ML algorithm was able to identify wild-type ATTR patients from a small 1:1 cohort with excellent performance (AUC 0.95); however, when attempting validation testing for unspecified “cardiac amyloidosis,” the algorithm exhibited a fair drop in performance (AUC 0.76-0.80).22 This evidence concerns the gene TTR and cardiac amyloidosis.